"
Safety and Efficacy of Racotumomab-Alum Vaccine as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer"
written by Eduardo Santiesteban, Leslie Perez, Sailyn Alfonso, Elia Neninger, Soraida Acosta, Yoana Flores, Maurenis Hernandez, Carmen Viada, Robin García, Meylán Cepeda, Daymys Estevez, Yoisbel Moreno, Amparo Macías,
published by
International Journal of Clinical Medicine,
Vol.5 No.14, 2014
has been cited by the following article(s):
[1]
|
Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy
Critical Reviews in Oncology/Hematology,
2021
DOI:10.1016/j.critrevonc.2021.103417
|
|
|
[2]
|
Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy
Critical Reviews in Oncology/Hematology,
2021
DOI:10.1016/j.critrevonc.2021.103417
|
|
|
[3]
|
Cellular and molecular immunology of lung cancer: therapeutic implications
Expert Review of Clinical Immunology,
2014
DOI:10.1586/1744666X.2014.975692
|
|
|